FDA decision regarding abuse deterrent Opana from Endo Pharma
Look for an FDA decision regarding Zohyrdro from Zogenics which is an extended release hydrocodone (pure) without any abuse deterrent properties
True, however too much control by Care Capital and others has been recognized as a problem. Possibly trying to spread their shares among institutional buyers. Will be able to determine more when we have a glimpse at who is buying these shares for their future.